Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han Purchases 24,900 Shares

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 24,900 shares of Burning Rock Biotech stock in a transaction that occurred on Friday, June 26th. The shares were acquired at an average price of $8.00 per share, with a total value of $199,200.00. Following the completion of the acquisition, the director directly owned 18,404,086 shares of the company’s stock, valued at $147,232,688. This represents a 0.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Yusheng Han also recently made the following trade(s):

• On Wednesday, June 24th, Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $8.00 per share, for a total transaction of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han bought 5,990 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han bought 104,650 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han purchased 111,110 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $9.00 per share, for a total transaction of $999,990.00.
• On Friday, June 12th, Yusheng Han bought 210,000 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $9.25 per share, for a total transaction of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han bought 24,760 shares of Burning Rock Biotech stock. The stock was bought at an average price of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Price Performance

BNR opened at $8.96 on Thursday. The stock has a fifty day moving average price of $12.79 and a 200 day moving average price of $20.08. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06. Burning Rock Biotech Limited Sponsored ADR has a 1 year low of $3.22 and a 1 year high of $41.72. The stock has a market cap of $94.26 million, a price-to-earnings ratio of -10.93 and a beta of 1.33.

Burning Rock Biotech (NASDAQ:BNR) last posted its earnings results on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($2.29) by $2.09. The company had revenue of $15.66 million during the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Analyst Ratings Changes

BNR has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. Wall Street Zen downgraded shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Burning Rock Biotech

Several institutional investors have recently bought and sold shares of BNR. Crcm LP boosted its stake in shares of Burning Rock Biotech by 121.8% in the 4th quarter. Crcm LP now owns 491,426 shares of the company’s stock valued at $9,902,000 after purchasing an additional 269,851 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Burning Rock Biotech by 13.8% during the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after purchasing an additional 4,290 shares in the last quarter. Prospera Financial Services Inc lifted its holdings in Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after purchasing an additional 6,430 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Burning Rock Biotech during the 4th quarter valued at about $220,000. Institutional investors and hedge funds own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.